Akeso, Summit's ivonescimab hits OS goal in Keytruda head-to-head

Akeso and Summit Therapeutics’ ivonescimab has demonstrated a statistically significant overall survival benefit over Merck’s Keytruda in the Phase 3 Harmoni-2 trial for first-line PD-L1-positive non-small cell lung cancer in Chinese patients, marking the fourth such positive OS trial for ivonescimab. The results bolster its potential to compete globally against Keytruda, although wider acceptance hinges on outcomes from the global Harmoni-3 trial.

This Wire brief sits within Fusion42's coverage of Biotech.